71666-48-3

Upstream product

• 1427549-78-7 1-(4-fluorophenyl)-2-(1-hydroxycyclohexyl)ethan-1-one 
• 108-94-1 cyclohexanone 
• 403-42-9 1-(4-fluorophenyl)ethanone 

Downstream Products

• 1427549-77-6 3-cyclohexyl-2-(4-fluorophenyl)-N-[2-(1H-indol-3-yl)ethyl]-1-methyl-1H-imidazo[1,2-b]pyrazole-7-carboxamide 
• 1427549-81-2 2-bromo-2-cyclohexyl-1-(4-fluorophenyl)ethanone 
• 1427549-83-4 methyl 3-cyclohexyl-2-(4-fluorophenyl)-1H-imidazo[1,2-b]pyrazole-6-carboxylate 
• 1427549-85-6 3-cyclohexyl-2-(4-fluorophenyl)-1H-imidazo[1,2-b]pyrazole-6-carboxylic acid 
• 1427549-87-8 methyl 3-cyclohexyl-2-(4-fluorophenyl)-1-methyl-imidazo[1,2-b]pyrazole-6-carboxylate 
• 1427549-89-0 3-cyclohexyl-2-(4-fluorophenyl)-1-methyl-1H-imidazo[1,2-b]pyrazole-6-carboxylic acid 
• 1427549-91-4 ethyl 3-cyclohexyl-2-(4-fluorophenyl)-1H-imidazo[1,2-b]pyrazole-7-carboxylate 
• 1427549-93-6 ethyl 3-cyclohexyl-2-(4-fluorophenyl)-1-methyl-imidazo[1,2-b]pyrazole-7-carboxylate 
• 1427549-95-8 3-cyclohexyl-2-(4-fluorophenyl)-1-methyl-1H-imidazo[1,2-b]pyrazole-7-carboxylic acid 
• 1427549-97-0 3-cyclohexyl-2-(4-fluorophenyl)-1-methyl-1H-imidazo[1,2-b]pyrazole 
• 1427549-55-0 ethyl (2E)-3-[4-({[1-({[3-cyclohexyl-2-(4-fluorophenyl)-1-methyl-1H-imidazo[1,2-b]pyrazole-6-yl]carbonyl}amino)cyclobutyl]carbonyl}amino)phenyl]prop-2-enoate 
• 1427549-56-1 (2E)-3-[4-[[1-[[3-cyclohexyl-2-(4-fluorophenyl)-1-methyl-imidazo[1,2-b]pyrazole-6-carbonyl]amino]cyclobutanecarbonyl]amino]phenyl]prop-2-enoic acid 
• 1427549-59-4 ethyl (2E)-3-[4-[[1-[[3-cyclohexyl-2-(4-fluorophenyl)-1-methyl-imidazo[1,2-b]pyrazole-7-carbonyl]amino]cyclobutanecarbonyl]amino]phenyl]prop-2-enoate 
• 1427549-61-8 (2E)-3-[4-({[1-({[3-cyclohexyl-2-(4-fluorophenyl)-1-methyl-1H-imidazo[1,2-b]pyrazole-7-yl]carbonyl}amino)cyclobutyl]carbonyl}amino)phenyl]prop-2-enoic acid 

Relevant academic research and scientific papers

COMPOUNDS FOR THE TREATMENT OF HCV

The present invention relates to viral polymerase inhibitors of formula (I), salts, solvates, hydrates, racemates, enatiomers and isomers thereof, in particular inhibitors of viral polymerases within the Flaviviridae family such as hepatitis C virus (HCV), processes for their preparation and their use in the treatment of Flaviviridae viral infection such as Hepatitis C virus (HCV) infections